CAMBRIDGE, Md., Jan. 25, 2017 (GLOBE NEWSWIRE) — ConverGene has entered into a Sponsored Research Agreement with University of Maryland, Baltimore. Under this agreement University of Maryland School of Medicine Professor Curt I. Civin, M.D., who is associate dean for research and director of the Center For Stem Cell Biology & Regenerative Medicine, will investigate the in vivo anti-leukemic effects of ConverGene’s lead drug candidates, CG223 and CG250. Acute Myelogenous Leukemia (AML) is a likely first disease target for these compounds.  The first-in-class anti-cancer drug candidates exhibit dual activity inhibiting both BET bromodomains and dopamine receptor 2 (DRD2) while maintaining an excellent safety profile. Dr. Civin’s lab is engaged through the agreement to:

1. Assess the toxicity of BET inhibitors to primary human hematopoiesis;
2. Identify novel synergies between ConverGene BET inhibitors and other anti-leukemic drugs.

ConverGene’s CEO, Dr. Jeff Strovel, commented, “We are excited to kick-off this new collaboration with UMB. Dr. Civin is world-renowned for his expertise in normal and neoplastic hematopoiesis. His insight and ability to advance our understanding of CG223 and CG250 mechanism of action are unparalleled.”

Dr. Civin added, “I look forward to determining the efficacy of these promising new targeted inhibitors against leukemias and their toxicity to normal hematopoiesis. We have reason to predict a large therapeutic window. In addition, we will pursue some exciting combinations of these drugs with other emerging anti-leukemic drugs. I am pleased to collaborate with a Maryland company, so that our collaborative research may create both cures and jobs close to home.”

Click here to read the rest of the story on BioBuzz.